BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Shahriar Koochekpour	Assistant Professor
eRA COMMONS USER NAME (credential, e.g., agency login) Skooch	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Shiraz University of Med. Sci. Shiraz, Iran	MD	1983-1990	Medicine
Shiraz University of Med. Sci. Shiraz, Iran	Residency	1990-1992	Pathology
University of London, London, U.K.	Ph.D.	1993-1996	Molecular Oncology

NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the attached sample.

A. Positions and Honors.

Positions and Employment

1996-1999: Postdoctoral Scientist, Molecular Oncology Section, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD.
2000-2001: Postdoctoral Fellow, Dept of Biochemistry and Molecular Biology, Stanley S. Scott Cancer Center, LSU-Health Sciences Center, New Orleans, LA.
2002-2005: Research-Assistant Professor, Department of Microbiology, Immunology, and Parasitology, Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA.
2005-pres: Assistant Professor (tenure-track), Department of Microbiology, Immunology, and Parasitology, Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA.
2006-pres: Adjunct Assistant Professor, Department of Biochemistry and Molecular Biology, LSU Health Sciences Center, New Orleans, LA.
2008-pres: Adjunct Assistant Professor of Urology, Department of Urology, LSU Health Sciences Center, New Orleans, LA.

Professional Societies

2008-pres Active member, Minority in Cancer Research (AACR)
2004-pres: Member, American Urological Association (AUA)
2004-pres: Active member, Society for Basic Urology Research (SBUR)
2003-pres: Active member, American Association for Cancer Research (AACR)

Other Professional Activities

Editorial tasks

2003-pres: Ad hoc Reviewer for peer-reviewed journals (*Cancer Lett, Eu. J. Cacer, Urology, Cancer Res, Clinical Cancer Res, Asian J Andrology, Clinical Prostate Cancer, Fertility and Sterility, Journal of Andrology, Molecular Biology Reports, Biological Chemistry, Journal of Urology, European Journal of Oncology, Molecular Endocrinology, FEBS letter, FASEB J, Biochemistry, BBA, Br. J. Cancer, Exp Biology & Medicine*).
2004-pres: Editorial Board, Asian J. Andrology.

2006-pres: Editorial Board, Atlas of Genetics and Cytogenetics in Oncology and Hematology.
2006-pres: Editorial Board of Consultants, Archives of Iranian Medicine (AIM), Iranian National Academy of Science & Art (INASA).
2008-pres: Editorial Board, The Open Prostate Cancer Journal
2009: Editorial Board, International Journal of Nephrology and Urology

2006-pres: Organizer of "Prostate Cancer Research Interest Group" at LSU Health Sciences Center/Stanley S. Scott Cancer Center, an effort to establish a prostate cancer-dedicated group for training in basic and translational research, presenting research data for critical discussion among investigators, sharing research materials and expertise. This group is composed of prostate cancer researchers from LSU Health Sci Center, Tulane University and Cancer Center, Xavier University.
2008: Biologically active recombinant human saposin C and PSAP. S/N: 61/030,307 USPTO

Patents:

2000: NCI-Invention Report: Employee Invention Report: NIH Reference No: DHHS: E-262-99/00

"Neutralizing Anti-HGF/SF Monoclonal Antibodies".
2007: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College assaignee. "Saposin C and receptors as target for treatment of benign and malignant disorders" US patent 7,166,691, January 23, 2007.

Other Research Activities

Establishment and characterization of the first primary androgen-sensitive PCa cell line (E006AA) derived from an African-American patient with an organ-confined PCa, E006AA. This cell line is not tumorigenic in SCID or nude mice and does not form colony in soft-agar. In support of prostate cancer research, Dr. Koochekpour has provided this cell line to prostate cancer investigators in different research institutions including: NIH/NCI (Bethesda), Texas MD-Anderson Cancer Center, Emory University/Molecular Urology and therapeutics program, Harvard Medical School, Duke University, University of North Carolina, Johns Hopkins University.

B. Selected peer-reviewed publications (in chronological order from a total of 38 publications)

1. Koochekpour, S., Merzak, A., Pilkington, G.J. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Letters, 102:209-215, 1996.

2. Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E., Hudson, E.A., Resau, J.H., and Vande Woude, G.F. Met and Hepatocyte Growth Factor expression in Human Gliomas. Cancer Research, 57:5391-5398, 1997.

3. Jeffers, M., Koochekpour, S., Fiscella, M., Sathyanarayana., and Vande Woude, G.F. Signaling Requirements for Oncogenic Forms of the Met Tyrosine Kinase receptor. Oncogene, 17:2691-2700, 1998.

4. Koochekpour, S., Jeffers, M., Wang, P.H., Gong, C., Taylor, G.A., Roessler, L.M., Stearman, R., Stetler-Stevenson, W.G., Kaelin Jr., W.G., Linehan, W.M., Klausner, R.D., Gnarra, J.R., and Vande Woude, G.F. The VHL Tumor Suppressor Gene Inhibits HGF/SF-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Mol Cell Biol, 19:5902-5912, 1999.

5. Webb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M., Sausville, E., Monks, A., and Vande Woude, G.F. The geldanamycins are potent inhibitors of the HGF/SF-Met-uPA-Plasmin proteolytic network. Cancer Research, 60:342-349, 2000.

6. Duesbery, N.S., Resau, J., Webb, C. P., Koochekpour, S., Koo, H. M., Leppla, S.H., and Vande Woude, G.F. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. *Proc Natl Acad Sci. USA*, 98: 4089-4094, 2001.

7. Koochekpour, S., Maresh, G., Katner, A., Parker-Johnson, K., Lee, T-J., Hebert, F. E., Kao, Y., and Rayford, W. Establishment and characterization of a primary African-American prostate cancer cell line, E006AA. Prostate, 60:141-152, 2004.

8. Koochekpour, S., Sartor, O., Lee, T-J., Zieske, Arthur., Patten, D. Y., Hiraiwa, M., Sandhoff, K., Remmel, N., and Minokadeh, A. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate, 61:114-123, 2004.

9. Sartor, O and Koochekpour, S. Stem Cells and Prostate Cancer. Clin Prostate Cancer, 3:11- 12, 2004.

10. Lee, T-L., Luftig, R., Sartor, O., and Koochekpour, S. Saposin C Promotes Survival and Prevents Apoptosis Via the PI3K/Akt-Dependent Pathway in Prostate Cancer Cells. Mol Cancer, 3: 31, 2004.

11. Koochekpour, S., Sartor, O., Hiraiwa, M., Lee, T-L., Rayford, W., Remmel, N, Sandhoff, K., Minokadeh, A., and Patten, D. Y. Saposin C Stimulates Growth and Invasion, Activates p42/44 and SAPK/JNK Signaling Pathways of MAPK and Upregulates uPA/uPAR Expression in Prostate Cancer and Stromal Cells. Asian J Andrology, 7, 147-158, 2005.

12. Gandhok, N. K., Looney S., Koochekpour, S., and Sartor, O. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. Urol Oncol, 23:163-167, 2005.

13. Koochekpour, S., Lee, T-J., Beroukhim, R., Hssieh, C-L., Hofer, M. D., Zhau, H. E, Hiraiwa. M., Sawyers, C.L., Luftig, R. B., Sandhoff, K., Pienta, K. J., Rubin, M. A., Sellers, W. R., and Sartor, O. Amplification and Overexpression of Prosaposin in Prostate Cancer and Other Malignant Cells. Genes, Chromosomes & Cancer, 44:351-64, 2005.

14. Koochekpour,S. PSAP (Prosaposin; Gene Card/Invited-Review Article) variant Gaucher disease)). URL:http://www.infobiogen.fr/services/chromcancer/Genes/PSAPID42980ch10q22.html. Atlas Genet Cytogenet Oncol Haematol, 10:370-384, 2006.

15. Koochekpour, S., Lee, T-J., Wang, R, Culig, Z., Delorme, N., Caffey, S., Marrero, L., and Aguirre, J. Prosaposin Upregulates AR and PSA Expression and Activity In Prostate Cancer Cells (LNCaP). Prostate, 67:178-189, 2007.

16. Koochekpour, S., Lee, T-J, Wang, R., Sun, Y., Delorme, N., Hiraiwa, M., Grabowski, G. A., Culig, Z., and Minokadeh, A. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP. J Cell Biochem, 110: 631-641, 2007.

17. Nair, S. S., Guo, Z., Mueller, J. M, Koochekpour, S., Qiu, Y., Tekmal, R. R, Schule, R., Kung, H. J, Kumar, R, Vadlamudi RK. PELP1/MNAR enhances androgen receptor functions through LIM-only coactivator FHL2. Mol Endocrinol. 21: 613-624, 2007.

18. Koochekpour, S., Lee, T-J., Sun, Y., Hu, S., Grabowski, G. A., Liu, Z., Garay, J. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells. J Cell Biochem, 14, 104(6): 2272-2285, 2008.

19. Singh G, Aras S, Zea AH, Koochekpour S, Aiyar A. Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains. J Virol. 2009 May;83(9):4227-35.

C. Research Support

Ongoing Research Support

1 P20 RR021970 (01) Ochoa (PI) 10/01/2005-09/30/2010
NIH/NCRR
Mentoring Translational Research in Louisiana
This COBRE proposal was an initiative to mentor promising junior scientists in their own specific field for translational cancer research.
Role: Leader of Project #1: Prosaposin, a novel target for immunotherapy of prostate cancer

Completed Research Support

1 R21 CA120625 Koochekpour (PI) 04/01/2006-03/31/2008
NCI/NIDDK
Prosaposin, a novel tumor marker for prostate cancer
In this study by using quantitative techniques and analyzing prosaposin expression level in serum samples and tissue microarray sections of prostate cancer patients, we investigated the potential of prosaposin as a tumor marker for prostate cancer.
Role: PI